See more : PIXTA Inc. (3416.T) Income Statement Analysis – Financial Results
Complete financial analysis of Silk Road Medical, Inc (SILK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Silk Road Medical, Inc, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Elanco Animal Health Incorporated (ELAN) Income Statement Analysis – Financial Results
- Regenx Tech Corp. (RGXTF) Income Statement Analysis – Financial Results
- Cello World Limited (CELLO.NS) Income Statement Analysis – Financial Results
- ZOY Home Furnishing Co.,Ltd (603709.SS) Income Statement Analysis – Financial Results
- Pinetree Capital Ltd. (PNP.TO) Income Statement Analysis – Financial Results
Silk Road Medical, Inc (SILK)
About Silk Road Medical, Inc
Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 177.13M | 138.64M | 101.48M | 75.23M | 63.35M | 34.56M | 14.26M |
| Cost of Revenue | 50.05M | 37.88M | 25.45M | 21.29M | 15.93M | 10.87M | 5.13M |
| Gross Profit | 127.09M | 100.76M | 76.03M | 53.94M | 47.43M | 23.68M | 9.13M |
| Gross Profit Ratio | 71.75% | 72.68% | 74.92% | 71.70% | 74.86% | 68.53% | 64.03% |
| Research & Development | 41.32M | 36.45M | 27.11M | 21.27M | 12.27M | 10.26M | 7.24M |
| General & Administrative | 144.57M | 115.97M | 96.17M | 75.33M | 62.86M | 34.82M | 20.26M |
| Selling & Marketing | 461.00K | 347.00K | 221.00K | 194.00K | 362.00K | 186.00K | 218.00K |
| SG&A | 145.03M | 116.32M | 96.39M | 75.52M | 63.22M | 34.82M | 20.26M |
| Other Expenses | 442.00K | -190.00K | -23.00K | -80.00K | -21.05M | -12.06M | 2.93M |
| Operating Expenses | 186.36M | 152.77M | 123.50M | 96.80M | 75.49M | 45.08M | 27.50M |
| Cost & Expenses | 236.41M | 190.64M | 148.94M | 118.09M | 91.42M | 55.95M | 32.63M |
| Interest Income | 9.96M | 2.53M | 198.00K | 1.10M | 1.66M | 189.00K | 34.00K |
| Interest Expense | 6.87M | 5.10M | 2.52M | 4.41M | 4.95M | 4.36M | 3.94M |
| Depreciation & Amortization | 3.79M | 3.17M | 1.92M | 1.39M | 1.29M | 517.00K | 128.72K |
| EBITDA | -45.08M | -46.74M | -45.55M | -41.47M | -46.17M | -32.75M | -18.25M |
| EBITDA Ratio | -31.32% | -35.82% | -46.61% | -55.51% | -41.68% | -94.78% | -107.20% |
| Operating Income | -59.27M | -52.00M | -47.47M | -42.86M | -28.07M | -21.40M | -18.37M |
| Operating Income Ratio | -33.46% | -37.51% | -46.78% | -56.97% | -44.30% | -61.91% | -128.87% |
| Total Other Income/Expenses | 3.53M | -3.01M | -2.34M | -4.51M | -24.35M | -16.24M | -982.00K |
| Income Before Tax | -55.74M | -55.01M | -49.81M | -47.37M | -52.42M | -37.63M | -19.36M |
| Income Before Tax Ratio | -31.47% | -39.68% | -49.09% | -62.96% | -82.73% | -108.89% | -135.76% |
| Income Tax Expense | 43.00K | 3.01M | 576.00K | 3.02M | 3.66M | -11.87M | 6.87M |
| Net Income | -55.74M | -58.02M | -50.39M | -50.39M | -56.07M | -37.63M | -19.36M |
| Net Income Ratio | -31.47% | -41.85% | -49.65% | -66.98% | -88.51% | -108.89% | -135.76% |
| EPS | -1.44 | -1.62 | -1.45 | -1.53 | -2.44 | -1.31 | -0.80 |
| EPS Diluted | -1.44 | -1.62 | -1.45 | -1.53 | -2.44 | -1.31 | -0.80 |
| Weighted Avg Shares Out | 38.80M | 35.78M | 34.64M | 32.97M | 22.96M | 28.71M | 24.05M |
| Weighted Avg Shares Out (Dil) | 38.80M | 35.78M | 34.64M | 32.97M | 22.96M | 28.71M | 24.05M |
Silk Road Medical Announces Investor Education Webcast with Key Opinion Leaders
SUNNYVALE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that the company will host an investor education webcast at 11:00...
Silk Road Medical to Present at the BofA Securities 2023 Healthcare Conference
SUNNYVALE, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will participate in the upcoming BofA Securities 2023 Healthcare...
Silk Road Medical to Report First Quarter 2023 Financial Results on May 9, 2023
SUNNYVALE, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the first quarter 2023 after...
Silk Road Medical: Today Best Nearby Cap-Gain Medical Equipment Stock Prospect
“A 3-5 month prospect from here of SILK share prices could reasonably range from a $47.07 low to a $61.27 high from its $47.29 present price, a gain of +29.6%." The result of 54 positions like today's in the past...
Silk Road Medical (SILK) Reports Q4 Loss, Tops Revenue Estimates
Silk Road Medical (SILK) delivered earnings and revenue surprises of 8.11% and 7.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Silk Road Medical, Inc (SILK) Q4 2022 Earnings Call Transcript
Silk Road Medical, Inc (NASDAQ:SILK ) Q4 2022 Results Conference Call February 28, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations Erica Rogers - Chief Executive Officer Lucas Buchanan - Chief Financial Officer and Chief Operating Officer...
What Makes Silk Road Medical (SILK) a New Strong Buy Stock
Silk Road Medical (SILK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Silk Road Medical to Present at the 41st Annual J.P. Morgan Healthcare Conference
SUNNYVALE, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming 41st Annual J.P....
Silk Road Medical (SILK) is a Great Momentum Stock: Should You Buy?
Does Silk Road Medical (SILK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Swiss National Bank Has $2.99 Million Stake in Silk Road Medical, Inc (NASDAQ:SILK)
Swiss National Bank increased its position in shares of Silk Road Medical, Inc (NASDAQ:SILK – Get Rating) by 4.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The...
Source: https://incomestatements.info
Category: Stock Reports